CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults
The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, October 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that abobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) be reimbursed for the symptomatic treatment of focal spasticity affecting the upper limbs in adults |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (7 pages) |